Aclaris Therapeutics, Inc. (ACRS) — Financial statements
Income statement, balance sheet, and cash flow for Aclaris Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 8↓58.2% | 19↓40.1% | 31↑5.0% | 30↑340.1% | 7 | |
| Cost of Revenue | 2↓25.1% | 3↓84.6% | 18↑51.2% | 12↑153.8% | 5 | |
| Gross Profit | 6↓64.0% | 16↑21.0% | 13↓26.0% | 18↑768.8% | 2 | |
| Operating Expenses | ||||||
| R&D Expenses | 53↑56.7% | 34↓65.9% | 98↑26.4% | 78↑77.6% | 44 | |
| General & Administrative Expenses | 22↓1.0% | 22↓28.6% | 31↑23.7% | 25↑6.4% | 24 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 22↓1.0% | 22↓28.6% | 31↑23.7% | 25↑6.4% | 24 | |
| Other Expenses | 7↓92.7% | 102↑638.4% | -19↓503.3% | 5↓80.7% | 24 | |
| Operating Expenses | 82↓48.0% | 158↑42.8% | 111↑2.7% | 108↑17.3% | 92 | |
| Total Costs & Expenses | 84↓47.6% | 161↑24.9% | 129↑7.5% | 120↑24.0% | 96 | |
| Operating Results | ||||||
| Operating Income | -76↑46.2% | -142↓45.8% | -97↓8.4% | -90↓0.1% | -90 | |
| Depreciation & Amortization | 0.45↓43.7% | 0.81↓6.5% | 0.86↑8.3% | 0.80↓13.7% | 0.92 | |
| EBITDA | -64↓24.7% | -52↑55.2% | -115↓36.9% | -84↓30.9% | -64 | |
| EBIT | -65↓23.6% | -53↑54.8% | -116↓36.6% | -85↓30.2% | -65 | |
| Interest & Other Income | ||||||
| Net Interest Income | 8↓4.0% | 8 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 8↓4.0% | 8 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -11↑87.2% | -89↓571.6% | 19↑503.3% | -5↑80.7% | -24 | |
| Other Income / Expenses | 11↑16.1% | 10↑16.0% | 9↑188.8% | 3↑358.0% | -1 | |
| Income Before Tax | -65↑50.8% | -132↓48.6% | -89↓2.2% | -87↑4.4% | -91 | |
| Income Tax Expense | 0.00 | 0.00↑100.0% | -0.37 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -65↑50.8% | -132↓49.3% | -88↓1.8% | -87↑4.4% | -91 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -65↑50.8% | -132↓49.3% | -88↓1.8% | -87↑4.4% | -91 | |
| Bottom-Line Net Income | -65↑50.8% | -132↓49.3% | -88↓1.8% | -87↑4.4% | -91 | |
| EPS (Basic) | -0.53↑69.0% | -1.71↓34.6% | -1.27↑4.5% | -1.33↑16.9% | -1.60 | |
| EPS (Diluted) | -0.53↑69.0% | -1.71↓34.6% | -1.27↑4.5% | -1.33↑16.9% | -1.60 | |
| Weighted Average Shares | 123↑58.7% | 77↑10.7% | 70↑7.0% | 65↑15.0% | 57 | |
| Weighted Average Diluted Shares | 123↑58.7% | 77↑10.7% | 70↑7.0% | 65↑15.0% | 57 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.